Please take a moment to review the important CE information on this page.

Click here for a list of CME Requirements by State.

Kidney Cancer: New Treatments Bring New Hope
is no longer available for CME credit.

Accreditation

Physicians

The National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.

NCCN designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurses

This activity is approved for 1.0 contact hour. National Comprehensive Cancer Network is an approved provider of continuing nursing education by PA State Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.

Approval as a provider refers to recognition of educational activities only and does not imply ANCC Commission on Accreditation or PA Nurses approval or endorsement of any product.

Kristina M. Gregory, RN, MSN, OCN, is our nurse planner for this educational activity.

Contact NCCN at webcasts@nccn.org.

Program Overview
Until a few years ago, patients with kidney cancer did not have many treatment choices. Surgery and/or difficult-to-tolerate immunotherapy were all that was available. Today, new options for robotically assisted surgery facilitate management of local disease, and, with the FDA approvals of new agents, a paradigm shift has occurred in the way patients with more advanced kidney cancer are treated. Patients now have access to these new treatments that have been shown to be effective in tumor reduction with fewer side effects than previous regimens, and clinicians now face questions about the sequence of therapies for advanced disease and whether adjuvant therapy is appropriate. In response to these issues, this program will focus on evolving data in the management of kidney cancer and their application in the current National Comprehensive Cancer Network (NCCN) Guidelines.

Learning Objectives
At the conclusion of this program, participants should be able to:

• Choose the appropriate imaging studies for the staging of kidney cancer
• Describe surgical techniques utilized in the management of kidney cancer
• Summarize the use of targeted agents for unresectable and recurrent kidney cancer

Target Audience
This educational activity is designed to meet the needs of physicians, nurses, and other clinical professionals who manage patients with cancer.

Faculty Disclosure Information
All faculty participating in NCCN continuing education activities are expected to disclose any conflict(s) of interest related to the content of their presentation(s) as defined by the ACCME's and ANCC's Standards for Commercial Support.

Commercial Support
Supported by educational grants from Novartis Oncology, Pfizer, and Wyeth.